Pediatrics

Modified Duke's Criteria

Major criteria: (1) Positive blood cultures for a typical IE organism from two separate cultures, or persistently positive cultures; (2) Evidence of endocardial involvement on echocardiography — vegetation, abscess, new valvular regurgitation, or new prosthetic valve dehiscence.

Minor criteria: predisposing cardiac condition/IV drug use, fever, vascular phenomena (arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial hemorrhage, Janeway lesions), immunologic phenomena (glomerulonephritis, Osler's nodes, Roth spots, positive rheumatoid factor), microbiological evidence not meeting major criteria.

Diagnosis established by: 2 major, OR 1 major + 3 minor, OR 5 minor criteria — categorized as definite, possible, or rejected.

Risk Factors — Congenital Heart Disease as Predominant Pediatric Risk Factor

Unlike adults (degenerative valve disease, prosthetic valves, IV drug use), congenital heart disease is the single most important pediatric risk factor, particularly lesions with turbulent, high-velocity flow (VSD, PDA, prosthetic material). Secundum ASD carries relatively low IE risk given lower turbulent flow.

Common Microbiology

Viridans group streptococci (dental procedures/poor oral hygiene) and Staphylococcus aureus (increasingly most common overall, more acute/fulminant, prosthetic material/catheter-associated) predominate; coagulase-negative staphylococci relevant in prosthetic valve/device IE; HACEK group organisms relevant when standard cultures are persistently negative.

Empirical Antibiotic Therapy

Combines an agent effective against staphylococci (including MRSA coverage, e.g., Vancomycin) with an agent providing streptococcal/Gram-negative coverage (broad-spectrum beta-lactam or aminoglycoside) — prolonged treatment courses (typically 4–6 weeks) once organism/susceptibility confirmed, reflecting the poorly-vascularized vegetation environment.

Clinical Presentation of Respiratory Diphtheria

Caused by toxin-producing Corynebacterium diphtheriae, presenting with a gray-white, adherent pseudomembrane over tonsils, pharynx, and/or larynx (firmly adherent; removal causes underlying mucosal bleeding — distinguishing from other exudative pharyngitis). Laryngeal extension risks mechanical airway obstruction, requiring vigilant monitoring and low threshold for early intubation/tracheostomy. Systemic toxin absorption causes myocarditis (leading cause of mortality, typically weeks 2–3) and peripheral neuropathy (palatal and other cranial nerve palsies, later generalized polyneuropathy).

Anti-Diphtheritic Serum (Antitoxin)

Diphtheria Antitoxin (DAT), an equine-derived preparation, is the key, time-critical treatment — given as early as possible based on clinical suspicion alone, without waiting for microbiological confirmation, since it can only neutralize circulating, not tissue-bound, toxin. Skin testing for hypersensitivity is typically performed before full-dose administration. Antibiotics (penicillin or erythromycin) are given concurrently to eliminate the organism and reduce transmission, but do not substitute for antitoxin.

Management of Malignant Pertussis

Fulminant presentation predominantly in infants <3 months, characterized by extreme leukocytosis (predominantly lymphocytosis, contributing to pulmonary vascular obstruction/hypertension), severe pulmonary hypertension, and refractory respiratory failure/shock with high mortality. Management is predominantly supportive/intensive: mechanical ventilation, pulmonary hypertension management, and in the most severe cases, exchange transfusion or leukapheresis to rapidly reduce extreme leukocytosis. Azithromycin remains mainstay antimicrobial, though its benefit at this stage is mainly reducing transmission. Maternal Tdap vaccination during pregnancy and cocooning strategies are the primary prevention approach.

Classification of AEFI

Causality Assessment

A structured, WHO-endorsed process applied to significant/serious AEFI: detailed clinical case review, eligibility/checklist assessment for known reactions, temporal relationship assessment, consideration of alternative explanations, and a structured algorithm yielding a final classification (consistent with causal association, coincidental/indeterminate, or unclassifiable).

Investigation Protocol

Any serious/significant reported AEFI triggers: immediate case investigation, assessment of the specific vaccine batch/lot (cross-referencing other reports for the same batch — quality defect concern), review of the immunization process/technique used, and reporting through the national AEFI surveillance system — essential for patient safety and public trust in immunization programs.

Clinical Triad

Caused by Leishmania donovani (Indian subcontinent), transmitted by infected female sandflies (Phlebotomus species): prolonged, often irregular fever (sometimes a double-rise pattern), hepatosplenomegaly (splenomegaly typically massive/prominent), and pancytopenia (bone marrow suppression plus hypersplenism-related sequestration). Additional features: progressive weight loss/wasting and skin hyperpigmentation ("black fever") in some patients.

Diagnostic Methods

• rK39 rapid immunochromatographic strip test: simple, rapid, field-deployable; primary first-line diagnostic tool in endemic areas including India.
• Bone marrow aspirate for LD (Leishman-Donovan) bodies: definitive, gold-standard method via direct visualization of intracellular amastigotes; particularly valuable when rK39 is equivocal/negative despite strong clinical suspicion, or in HIV co-infection.

Treatment

Liposomal Amphotericin B is now the preferred first-line treatment in the Indian subcontinent — excellent efficacy including in antimonial-resistant regions, improved safety/tolerability vs conventional amphotericin B deoxycholate, and effective single-dose/short-course regimens. This represents a shift from pentavalent antimonials (e.g., sodium stibogluconate), which have become unreliable first-line therapy in parts of Bihar given documented resistance. Alternatives: Miltefosine (first oral agent; teratogenicity concern limits use in women of childbearing potential) and Paromomycin (aminoglycoside, sometimes used in combination).

Pathogenesis of Rheumatic Carditis

ARF develops as a delayed, autoimmune sequela of Group A Streptococcal pharyngitis (not skin infection — distinguishing it from post-streptococcal GN), typically 2–4 weeks after the initiating infection, in genetically susceptible individuals. Mechanism: molecular mimicry — streptococcal M protein shares epitope similarity with cardiac myosin/sarcolemmal proteins, causing cross-reactive autoimmune injury to heart valves (mitral > aortic), myocardium, and pericardium (pancarditis in severe form). Recurrent carditis leads to progressive valvular scarring — Rheumatic Heart Disease (RHD).

Jones Criteria (2015 Revision) — A Risk-Stratified Framework

Diagnostic thresholds differ between low-risk populations (ARF incidence ≤2/100,000 school-age children/year, or RHD prevalence ≤1/1000) and moderate/high-risk populations (includes most of India), reflecting a higher pre-test probability in higher-burden settings.

• Major criteria: carditis (clinical and/or subclinical — echocardiographic detection is a key 2015 addition), polyarthritis (moderate/high-risk populations additionally accept monoarthritis or polyarthralgia as major), chorea, erythema marginatum, subcutaneous nodules.
• Minor criteria: risk-stratified fever/ESR/CRP thresholds; arthralgia counts as minor only in low-risk populations (since it's elevated to major in moderate/high-risk populations).

Initial ARF episode diagnosis: evidence of preceding GAS infection PLUS (2 major, OR 1 major + 2 minor). Recurrent ARF in moderate/high-risk populations with established prior disease: 2 minor criteria alone plus evidence of preceding streptococcal infection.

Primary Prophylaxis

Prompt, adequate treatment of the initiating streptococcal pharyngitis itself — oral Penicillin V for 10 days, or a single dose of IM Benzathine Penicillin G (better adherence) — effective if given within ~9 days of symptom onset, reliably preventing subsequent ARF.

Secondary Prophylaxis

Long-term prophylaxis in patients with confirmed prior ARF: Benzathine Penicillin G IM every 3–4 weeks (3-weekly interval preferred in higher-risk settings/more severe carditis), or oral Penicillin V twice daily (less reliable given adherence dependence). Duration is individualized: minimum duration/age for ARF without carditis; longer for carditis without persistent valvular disease; lifelong for established persistent rheumatic valvular heart disease.

Definitions

Sepsis in children is now defined (per the pediatric-specific Phoenix Sepsis Criteria, 2024, which have superseded the adult-derived SIRS-based definitions previously used) as suspected or confirmed infection with an accompanying Phoenix Sepsis Score ≥2, incorporating dysfunction across four organ systems: respiratory, cardiovascular, coagulation, and neurological — each scored 0–3 based on defined criteria. Septic shock is defined as sepsis with a cardiovascular Phoenix sub-score ≥1, reflecting cardiovascular dysfunction requiring vasoactive support, significant hypotension for age, or lactate elevation with additional cardiovascular criteria. This represents an important shift from the older SIRS-based (temperature, heart rate, respiratory rate, white cell count) definitions, which were recognized as poorly specific in the pediatric population.

Recognition — The Critical First Step

Early recognition remains the single most important determinant of outcome, given the well-established, dose-response relationship between time-to-treatment and mortality. Red flags include: altered mental status, prolonged capillary refill (>3 seconds, though both “cold” shock with delayed refill and vasodilated “warm” shock with flash capillary refill occur in children, distinct from the classically taught single “cold shock” pattern), mottled/cool extremities, weak peripheral pulses, tachycardia disproportionate to fever/agitation, and hypotension (a late, decompensated finding in children, given their greater capacity for peripheral vasoconstriction — normotensive septic shock is common and should not provide false reassurance).

Fluid Resuscitation — The Major Guideline Shift

The 2020 SSC pediatric guidelines represent a deliberate move away from the older, rigid “40–60 mL/kg in the first hour, reassess after each 10–20 mL/kg bolus” ACCM/PALS-derived teaching, reflecting evidence (notably the FEAST trial from resource-limited African settings, which showed increased mortality with aggressive fluid bolus therapy in febrile, critically ill children without access to advanced respiratory/inotropic support) that indiscriminate, aggressive fluid resuscitation is not uniformly beneficial and can cause harm in some contexts.

• Settings with ICU resources (mechanical ventilation, inotropic support): up to 40–60 mL/kg bolus fluid over the first hour, in aliquots (10–20 mL/kg boluses), with mandatory reassessment for fluid overload after each bolus (hepatomegaly, new/worsening crackles, worsening oxygen requirement, gallop rhythm)
• Settings without ICU resources (the FEAST trial context): bolus fluid therapy is recommended against, in favor of cautious maintenance-rate fluid administration
• Balanced/buffered crystalloids (Ringer's lactate/Plasma-Lyte) are now generally preferred over 0.9% normal saline, given evidence of reduced hyperchloremic metabolic acidosis and AKI risk

Vasoactive Agent Selection

For fluid-refractory shock, the first-line vasoactive agent is now Epinephrine or Norepinephrine, rather than Dopamine — a significant, frequently-tested shift, based on evidence including a pediatric RCT (Ventura et al.) showing epinephrine associated with improved survival vs dopamine, plus dopamine's less favorable adverse effect profile (arrhythmias, relative immunosuppressive/endocrine effects) at higher doses.

Dopamine is now a second-line/alternative agent where epinephrine/norepinephrine are unavailable. For catecholamine-refractory shock: vasopressin (refractory vasodilatory/warm shock) and milrinone or dobutamine (shock with significant myocardial dysfunction despite adequate preload/afterload optimization) may be added.

Target Hemodynamic Parameters

Resuscitation targets favor holistic, multi-parameter assessment: normalization of heart rate for age, capillary refill <2–3 seconds, normal mental status, adequate urine output, and normalized/normalizing lactate — with blood pressure targets generally set at achieving at least the 5th percentile for age (a “normal” BP alone does not exclude compensated shock). Point-of-care ultrasound (IVC characteristics, cardiac contractility) is increasingly used to guide fluid/vasoactive titration.

Adrenal Insufficiency and Corticosteroid Use

Genuinely controversial and an area of evolving guidance: 2020 SSC guidelines make a weak recommendation against routine IV hydrocortisone for fluid-responsive septic shock, while suggesting it may be considered specifically for children with fluid-refractory, catecholamine-resistant septic shock — reflecting critical illness-related corticosteroid insufficiency in this more severe subgroup. Emphasis throughout is on individualized judgment, not routine blanket administration.

Source Control and Antimicrobial Therapy

Broad-spectrum empirical antibiotics should be administered as early as possible, ideally within one hour of recognition of septic shock. Blood cultures should be obtained but must not delay antibiotics. Antibiotic choice is guided by suspected source, age, immune status, and local resistance; prompt source control (abscess drainage, infected line removal, surgical management of an intra-abdominal source) is pursued in parallel.

WHO Growth Standards (2006) — A “Standard,” Not Merely a “Reference”

A critical conceptual point: the WHO Multicentre Growth Reference Study (2006), despite its name, produced what is more accurately termed a growth standard — describing how children SHOULD grow under optimal conditions, rather than simply how a particular reference population actually did grow (as an older-style “reference” chart, such as the NCHS/CDC growth reference, represented). The WHO standard was constructed using a carefully selected, multi-country cohort of healthy, breastfed infants raised with minimal growth constraints (adequate nutrition, non-smoking mothers, term birth, absence of significant morbidity) — a prescriptive, aspirational standard applicable across populations globally, rather than a population-specific descriptive reference. This is the fundamental reason the WHO 2006 standards are now preferred internationally over the older CDC/NCHS reference charts (based predominantly on formula-fed American infants, showing a somewhat different, less optimal first-year trajectory compared to the WHO standard's breastfed reference population).

IAP Growth Charts (2015)

An India-specific adaptation and update, incorporating contemporary Indian pediatric anthropometric data, intended to reflect the Indian pediatric population's specific growth patterns and secular trends, while remaining broadly consistent with the WHO standard framework for the youngest age groups (0–5 years, where the WHO's prescriptive philosophy is considered most appropriate). The IAP charts extend growth monitoring guidance through adolescence with India-specific data, addressing a gap where WHO standard coverage becomes less complete for older childhood/adolescent growth in the Indian context.

Interpretation of Z-Scores

The z-score expresses how far, and in which direction, an individual measurement deviates from the median of the reference/standard population, in standard deviation units — more statistically precise and comparable than percentiles alone, particularly valuable at the extremes of the distribution (where percentile differences compress and become less discriminating, whereas z-scores remain linearly interpretable far from the median).

• Weight-for-height z-score — classifies acute malnutrition/wasting (z <-2 = moderate acute malnutrition; <-3 = severe acute malnutrition)
• Height-for-age z-score — classifies stunting/chronic malnutrition (z <-2)
• Weight-for-age z-score — composite measure reflecting both acute and chronic status, used for underweight classification
• A z-score of 0 represents the exact median; +2/-2 is the commonly used boundary for defining the “normal” range in many screening contexts

Height Velocity Charts

Rather than relying solely on a single cross-sectional height plotted against a standard curve, height velocity charts plot the rate of linear growth over time (cm/year, from serial measurements) against age-specific normal velocity standards — particularly valuable for early detection of a growth disorder before absolute height has fallen to a clearly abnormal percentile/z-score. A child growing at persistently subnormal velocity will eventually cross percentile lines downward on a standard chart, but height velocity monitoring identifies the abnormal pattern earlier, before the cumulative deficit becomes obviously apparent — a particularly sensitive tool for early identification of growth hormone deficiency, hypothyroidism, or other growth-impairing chronic conditions.

Mid-Parental Height Calculation

• Boys: [(Father's height + Mother's height + 13 cm) / 2]
• Girls: [(Father's height + Mother's height − 13 cm) / 2]

The calculated mid-parental height represents the center of an expected target height range, typically spanning approximately ±8.5 cm (roughly the 3rd–97th percentile of expected outcomes given parental heights) — providing an individualized reference point for assessing whether a child's growth trajectory is consistent with genetic potential (supporting familial short/tall stature) or significantly discordant (raising concern for pathological short/tall stature requiring further evaluation). This calculation is central to the short stature diagnostic algorithm (Q68).

Early Red Flags in Infancy and Toddlerhood

• By 12 months: absence of babbling, pointing, or other meaningful gestures; lack of response to name when called
• By 16 months: no single spoken words
• By 18–24 months: lack of joint attention (not pointing to show interest/share enjoyment — distinct from pointing to request, which can be relatively preserved), reduced/absent eye contact, limited/absent social smiling, lack of interest in pretend play, preference for solitary/repetitive play
• By 24 months: no meaningful two-word spontaneous phrases (not simply echoed/repeated phrases)
• At any age — any loss of previously acquired language or social skills (developmental regression) is a particularly significant red flag warranting urgent evaluation, given its strong ASD association (and the need to distinguish it from other regression causes including neurometabolic or epileptic encephalopathy conditions)
• Additional red flags: unusual repetitive motor mannerisms (hand-flapping, spinning), atypical/intense/narrow interests, unusual sensory responses, difficulty with transitions/routine changes

DSM-5 Diagnostic Criteria — A Structural Shift from DSM-IV

DSM-5 consolidated the previously separate DSM-IV subtypes (Autistic Disorder, Asperger Syndrome, Childhood Disintegrative Disorder, PDD-NOS) into a single, unified Autism Spectrum Disorder category, with specified severity levels (Level 1, requiring support; Level 2, requiring substantial support; Level 3, requiring very substantial support) — reflecting evidence that the previous categories were not reliably distinguishable clinical entities.

DSM-5 requires deficits across TWO core domains (reduced from DSM-IV's three domains):

1. Persistent deficits in social communication and social interaction across multiple contexts — social-emotional reciprocity, nonverbal communicative behaviors (eye contact, gestures, facial expression), and developing/maintaining/understanding relationships
2. Restricted, repetitive patterns of behavior, interests, or activities — stereotyped/repetitive motor movements or speech, insistence on sameness, highly restricted/fixated interests, and hyper-/hypo-reactivity to sensory input (explicit sensory feature inclusion is a notable DSM-5 addition)

Symptoms must be present in the early developmental period (though may not become fully apparent until social demands exceed capacity) and cause clinically significant functional impairment.

Screening Tools

M-CHAT-R/F (Modified Checklist for Autism in Toddlers, Revised, with Follow-Up) — the most widely used, validated tool, for the 16–30 month age range, a parent-completed 20-item questionnaire with a structured follow-up interview for children screening positive — this two-stage structure improves positive predictive value, reducing false-positive screens proceeding to unnecessary full diagnostic evaluation. Universal ASD screening with M-CHAT-R/F at the 18-month and 24-month well-child visits is now widely recommended standard practice.

Multidisciplinary Behavioral Interventions

• Applied Behavior Analysis (ABA) — the most extensively evidence-supported, structured behavioral intervention using systematic reinforcement principles
• Speech and language therapy — addresses core communication deficits and associated language delay
• Occupational therapy — sensory processing difficulties, fine motor skills, activities of daily living
• Social skills training — targets core social interaction deficits
• Parent-mediated intervention — trains caregivers to implement evidence-based strategies in everyday activities, extending intervention into the natural environment
• Educational intervention/IEP — essential, ongoing component extending into school-age and later development
• Pharmacological management — limited, targeted role for associated symptoms (significant irritability/aggression — risperidone and aripiprazole are the two FDA-approved agents for this in ASD) or co-occurring conditions (ADHD, anxiety), not the core ASD features, for which no disease-modifying pharmacotherapy exists

Definitions

Global Developmental Delay (GDD) refers to significant delay (generally >2 SD below the mean, or failure to meet expected milestones) in two or more developmental domains (gross/fine motor, speech/language, cognition, social/personal, activities of daily living), typically applied to children under 5 years (below the age at which formal, standardized IQ testing becomes reliably valid — beyond this age the term “Intellectual Disability” is applied instead, see Q78) — an important, frequently-tested age-based terminological distinction.

Etiological Evaluation — A Systematic, Structured Approach

History: prenatal (maternal illness, substance exposure, TORCH infections), perinatal (birth asphyxia, prematurity, neonatal complications including hyperbilirubinemia/kernicterus), family history (consanguinity, of particular relevance in many Indian contexts, and family history of developmental disorders/intellectual disability), and a detailed developmental history — particularly whether the pattern reflects a static encephalopathy versus a progressive, deteriorating course (a critical branch point: progressive course strongly raises concern for a neurodegenerative or metabolic disorder requiring urgent, targeted workup).

Examination: comprehensive general/neurological exam including dysmorphic features (genetic syndrome suspicion), head circumference (micro-/macrocephaly, Q76), skin examination (neurocutaneous stigmata — neurofibromatosis, tuberous sclerosis), organomegaly (storage disorder suspicion), and detailed tone assessment (hypotonia vs spasticity/hypertonia).

Structured etiological categories: genetic/chromosomal (Down syndrome, Fragile X syndrome, and less common conditions increasingly identified via expanded genetic testing), metabolic/inborn errors of metabolism (particularly important given some are specifically treatable — genuinely actionable identification), structural brain abnormalities (via neuroimaging), perinatal insult (hypoxic-ischemic injury, IVH, PVL, kernicterus), congenital infection (TORCH), environmental/psychosocial (significant deprivation/neglect — considered only after excluding organic causes, with careful sensitive clinical judgment), and idiopathic (a substantial proportion remain unidentified despite thorough evaluation).

Investigations (guided by clinical picture, not indiscriminate):

• Neuroimaging (MRI preferred over CT) — particularly with microcephaly/macrocephaly, focal neurological findings, or a regressive/progressive course
• Metabolic screening — specific inborn error testing where clinically indicated
• Genetic testing — Chromosomal Microarray (CMA) is now widely recommended as first-tier for unexplained GDD/intellectual disability (higher diagnostic yield vs standard karyotyping for submicroscopic copy number variants), with Fragile X testing and increasingly Whole Exome Sequencing (WES) as further tiers where CMA/initial evaluation doesn't yield a diagnosis
• Hearing and vision screening — essential, since unrecognized sensory impairment can masquerade as or compound apparent delay, and is readily treatable if identified

Role of Early Intervention Centers

Early Intervention Services (in India, integrated within broader national programs such as Rashtriya Bal Swasthya Karyakram) provide structured, multidisciplinary intervention (physiotherapy, occupational therapy, speech therapy, special educator input, family/caregiver training) delivered as early as possible following identification — reflecting the neuroscientific principle of early brain plasticity, whereby intervention during the period of maximal neuroplasticity yields substantially greater developmental gains than equivalent later intervention, making timely referral (rather than passive “wait and watch”) a central, actionable management principle.

Classification of Short Stature

• Familial (Genetic) Short Stature: height, while below population average, is appropriately consistent with the calculated mid-parental height target (Q65) — normal growth velocity, bone age concordant with chronological age, puberty at a normal time; a normal variant, not pathological
• Constitutional Delay of Growth and Puberty (CDGP): short for chronological age during childhood, but normal growth velocity, with bone age delayed relative to chronological age — a delayed maturational tempo rather than reduced ultimate growth potential; puberty is delayed but eventually occurs, with normal adult height achieved later than peers; often a positive family history of similarly delayed growth/puberty in a parent; key distinguishing feature vs familial short stature is the delayed bone age
• Pathological Short Stature: height discordant from the genetic target, and/or subnormal growth velocity (a particularly important, sensitive early indicator) — underlying causes span endocrine disorders (GH deficiency, hypothyroidism, Cushing syndrome), chronic systemic disease (CKD, IBD, celiac disease, chronic cardiac/pulmonary disease), genetic/syndromic causes (Turner syndrome, skeletal dysplasias), and psychosocial/nutritional deprivation

Diagnostic Algorithm

Careful anthropometric assessment (accurate height, growth velocity from serial measurements, mid-parental height calculation) → detailed history/examination (dysmorphic features, chronic systemic disease signs, pubertal staging) → bone age assessment as a central, pivotal step (Q83) → targeted laboratory investigation where a pathological cause is suspected (thyroid function, IGF-1/IGFBP-3 as GH axis screening markers, celiac screening, renal/hepatic function, karyotype in girls given Turner syndrome's subtle presentation).

Bone Age Assessment's Role

Bone age concordant with chronological age supports familial short stature (normal variant, no treatment); bone age significantly delayed supports either CDGP (normal variant, delayed tempo) or, with other concerning features/abnormal velocity, a pathological cause requiring further evaluation. Bone age is also used to predict adult height potential and to time/monitor response to growth-promoting therapy.

Indications for Growth Hormone Therapy

Established indications: confirmed GH deficiency (via dynamic stimulation testing, given the limitations of single random GH measurements given pulsatile secretion), Turner syndrome (used even without demonstrable GH deficiency, given evidence of final adult height benefit in this syndromic population), Chronic Kidney Disease-associated growth failure, Small for Gestational Age (SGA) birth with failure to catch up by a defined age, Prader-Willi syndrome, and certain other specific syndromic/genetic conditions with an established evidence base. GH therapy is not indicated for simple familial short stature or CDGP, where growth proceeds along an appropriate genetically-determined trajectory.